BioNeutra Global Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Other
  • ISIN: CA09073L1067
CAD
0.03
-0.01 (-33.33%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About BioNeutra Global Corp. stock-summary
stock-summary
BioNeutra Global Corp.
Pharmaceuticals: Other
BioNeutra Global Corporation is engaged in the research and development, production and commercialization of food ingredients for neutraceutical, functional and mainstream foods. The Company focuses on oligosaccharides. The Company's product, VitaFiber, which is a functional and health food ingredient made from agricultural products. The Company produces VitaFiber using its processes that transforms starch molecules from agriculture cereal crops, including corn, wheat, barley, potato, or tapioca into the functional health molecules of isomalto-oligosaccharide (IMO). The Company's VitaFiber is a sweet fiber, providing low calorie and soluble prebiotic fiber for human digestive health and it is also non-genetically modified organisms (GMO), sugar-free and gluten-free. The Company's VitaFiber-IMO products include a dietary fiber, a prebiotic, manages gastrointestinal health and a low calorie health sweetener.
Company Coordinates stock-summary
Company Details
9608 - 25 Avenue NW , EDMONTON AB : T6N 1J4
stock-summary
Tel: 1 780 4661481
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. David Hancock
Chairman of the Board
Dr. Jianhua Zhu
President, Chief Executive Officer, Director
Mr. Bill Smith
Vice Chairman of the Board
Mr. Warren Cabral
Director
Mr. Branko Jankovic
Director
Mr. C. H. William Cheung
Independent Director
Mr. Lionel Eshleman
Independent Director
Ms. Huifen Zhang
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Sep 2024)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals: Other

stock-summary
Market cap

CAD 2 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.56

stock-summary
Return on Equity

7.41%

stock-summary
Price to Book

-0.25